Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02302846

Study of MLN9708 as Maintenance Therapy for Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) in Remission
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if ixazomib can prevent AML or MDS from coming back in patients who are in remission. The safety of this drug will also be studied.

Status: 
Recruiting
Study Date: 
Sun, 03/01/2015 to Mon, 03/01/2021
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Ixazomib 4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle. Other Name: MLN9708